Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPER-trial Hyperemic Myocardial Perfusion by Adenosine at Different Doses
2023-505248-20-00Phase 4Authorised
- Sponsor
- Region Skåne
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adenosine in Chronic Coronary Syndrome (CCS) and heart failure (HF), sponsored by Region Skåne. Primary endpoint: Myocardial hyperemia measured by quantitative myocardial perfusion CMR imaging. Planned start Mar 2024; status: authorised.
02
Drugs
adenosine
03
Conditions
Chronic Coronary Syndrome (CCS)heart failure (HF)
Beyond the preview
Go deeper on 2023-505248-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505248-20-00.